SKYE SKYE BIOSCIENCE INC
- 12.000
- -0.050-0.41%
- 12.000
- 0.0000.00%
SKYE BIOSCIENCE INC News
Skye Bioscience, Inc.'s (NASDAQ:SKYE) Last Week's 13% Decline Must Have Disappointed Private Equity Firms Who Have a Significant Stake
Skye Bioscience Inc Files For Mixed Shelf Of Up To $300M - Sec Filing
Skye Bioscience Inc Files For Mixed Shelf Of Up To $300M - Sec Filing
SKYE BIOSCIENCE INC | 10-Q: Quarterly report
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of
Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program | NASDAQ:SKYE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSol
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of nov
Skye Bioscience to Present at Upcoming Investment Conferences
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Skye Bioscience Initiated at Outperform by Oppenheimer
Skye Bioscience Initiated at Outperform by Oppenheimer
Skye Bioscience (SKYE.US) was first covered by Oppenheimer, which gave it an superior market rating, with a target price of $25.00.
Skye Bioscience (SKYE.US) was first covered by Oppenheimer, which gave it an superior market rating, with a target price of $25.00.
Oppenheimer Initiates Coverage On Skye Bioscience With Outperform Rating, Announces Price Target of $25
Oppenheimer analyst Jay Olson initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Outperform rating and announces Price Target of $25.
Skye Bioscience to Uplist to Nasdaq Global Market
Skye Bioscience Stock Target Raised to $20 on Study Progress
On Thursday, Skye Bioscience Inc. (OTC: SKYE) saw its price target increased to $20 from $12 by a Piper Sandler analyst, who also reaffirmed an Overweight rating on the stock.
Piper Sandler Reiterates Overweight on Skye Bioscience, Raises Price Target to $20
Piper Sandler analyst Edward Tenthoff reiterates Skye Bioscience with a Overweight and raises the price target from $12 to $20.
Skye Bioscience Announces $40 Million Private Placement Equity Financing
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB:SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and
Medical Marijuana Market Expected to Grow at 22% CAGR Through 2027
Skye Bioscience Completes Phase 2a Glaucoma Drug Trial
Skye Bioscience, Inc. (OTCQB: SKYE), a biotechnology company specializing in the development of therapeutic drugs targeting the endocannabinoid system, has announced the completion of its Phase 2a clinical trial for SBI-100 Ophthalmic Emulsion (OE), a novel treatment for patients with elevated intraocular pressure (IOP) related to glaucoma or ocular hypertension.
Analysis
Price Target
No Data
